Abstract
Objective To summarize the situations and characteristics of adverse drug reactions (ADR) of bevacizumab (Bev) combined with chemotherapy in treatment of advanced colorectal cancer. Methods The medical data of the patients with advanced colorectal cancer who received Bev combined with chemotherapy in Shanxi Tumor Hospital from April 2010 to December 2016 were collected for retrospective analysis. The sexual distinction, age, therapeutic regimen, time of using Bev, types and grades of adverse reactions which were related to chemotherapy and Bev respectively, the time from medication to appearance of ADR, and the patients′ outcomes were comparied. Results A total of 83 patients were enrolled in the study. Of them, 39 were males and 44 were females. Fifty-eight cases were 6 periods), and combined with different chemotherapy regimens (mFOLFOX, FOLFIRI and fluorouracil) showed that there were no significant differences between the incidences of ADRs related to chemotherapeutic drugs and Bev among the groups of different clinical features. The proportion of levels III and IV ADRs related to chemotherapeutic drugs were higher than those of Bev combining with single drug regimen of 5-FU (P 0.05). Conclusions The main ADRs caused by Bev combined with different chemotherapies in treatment of advanced colorectal cancer are ADR related to chemotherapeutic drugs. The ADRs associated with chemotherapeutic drugs and Bev are level Ⅰ-Ⅱ mainly and had better safety. Key words: Colorectal neoplasms; Bevacizumab; Antineoplastic combined chemotherapy protocols; Drug toxicity
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have